Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Jul 26;21(12):2136–2140. doi: 10.1016/j.bbmt.2015.07.018

Figure 1. Study Schema.

Figure 1

Patients with relapsed/refractory HL were treated with brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks for maximum of 4 cycles. Radiographic assessment was done at the end of cycle 2 with CT or CT/PET scan. Patients were allowed to continue study if they achieved CR/PR/SD after 2 cycles. Radiographic assessment at end of study was done with CT/PET scan. Patients who achieved CR went directly to AHCT. Patients who achieved PR had the option of going directly to AHCT or receiving other salvage chemotherapy by investigators choice.

*XRT denotes local radiation therapy.